NCT00419367
No Longer Available
Not Applicable
Compassionate Use of Vorinostat (MK0683) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma
ConditionsLymphoma, T-Cell, Cutaneous
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lymphoma, T-Cell, Cutaneous
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- No Longer Available
- Last Updated
- 3 years ago
Overview
Brief Summary
In an effort to allow patients continued access to vorinostat outside of the base study, patients that are actively receiving study medication will discontinue from this study and receive vorinostat via another method supported by the SPONSOR (e.g. Named Patient Program (NPP)). For those institutions that do not allow receipt of an investigational therapy outside of a clinical trial, patients that are actively receiving study medication and
continue to meet eligibility will transition to an extension phase of the study and the base study will be closed.
The extension phase will begin as soon as the protocol amendment is implemented.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Advanced cutaneous T-cell lymphoma on or following two systemic therapies
- •Female participants must have a negative serum pregnancy test within 3 days of the first dose of vorinostat
- •Female participants must have finished menopause, or are surgically sterilized, or agree to use 2 adequate barrier methods of contraception
- •Male participants must agree to use 2 adequate barrier methods of contraception
- •To be treated on extension phase of study participant must have been treated on the base study for Protocol 042
Exclusion Criteria
- •Currently receiving any potential histone deacetylase (HDAC) inhibitor (e.g. valproic acid)
- •Currently receiving any other systemic therapy for CTCL. Corticosteroids that are similar in strength to 20 mg of prednisone daily are permitted
- •Pregnant or lactating
- •Known allergy to any component of the study drug
- •Eligible for any other study of vorinostat in CTCL patients
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)Advanced CancerNCT00907738Merck Sharp & Dohme LLC27
Unknown
Phase 1
Clinical Trial of SAHA in Patients With Breast CancerBreast CancerNCT00416130National University Hospital, Singapore49
Active, not recruiting
Not Applicable
Compassionate Use of Vorinostat (MK-0683) for the Treatment of Patients with Advanced Cutaneous T-Cell LymphomaCutaneous T-cell lymphoma (CTCL)MedDRA version: 8.1Level: LLTClassification code 10011677Term: Cutaneous T-cell lymphomaEUCTR2006-003879-12-SIMerck & Co, Inc.100
Active, not recruiting
Not Applicable
Compassionate Use of Vorinostat (MK-0683) for the Treatment of Patients with Advanced Cutaneous T-Cell LymphomaEUCTR2006-003879-12-DKMerck & Co., Inc.100
Active, not recruiting
Not Applicable
Compassionate Use of Vorinostat (MK-0683) for the Treatment of Patients with Advanced Cutaneous T-Cell Lymphoma - NDPatients with cutaneous manifestations of CTCL who have progressive, persistent, or recurrent cutaneous T-cell lymphoma on or following two systemic therapies.MedDRA version: 6.1Level: HLGTClassification code 10025321EUCTR2006-003879-12-ITMERCK SHARP DOHME100